A case of iatrogenic growth retardation induced by a corticosteroid-containing anti-allergic drug

Horm Metab Res. 1995 Aug;27(8):376-8. doi: 10.1055/s-2007-979982.

Abstract

A nine-year old boy developed reduced growth velocity at the age of seven. The peak plasma growth hormone (GH) response to 3,4-dihydroxyphenylalanine, GH-releasing factor and insulin was 10.2, 8.1 and 7.6 micrograms/l, respectively, suggesting that the GH reserve was slightly reduced. Serum cortisol was undetectable and urinary excretion of 17-hydroxycorticosteroid was low (0.22-0.31 mg/day), but there were no physical or biochemical signs of adrenocortical insufficiency. He had taken an anti-allergic drug containing 0.25 mg of betamethasone and 2 mg of d-chlorpheniramine maleate per tablet for about 2 years to treat allergic rhinitis. Catch-up growth occurred when this drug was stopped. The present case suggests that daily administration of 0.25 mg of betamethasone can induce growth retardation and that ingestion of corticosteroid-containing preparations needs to be excluded in children who develop short stature without other symptoms.

Publication types

  • Case Reports

MeSH terms

  • 17-Hydroxycorticosteroids / urine
  • Anti-Allergic Agents / adverse effects*
  • Anti-Allergic Agents / therapeutic use
  • Betamethasone / adverse effects*
  • Betamethasone / therapeutic use
  • Child
  • Chlorpheniramine / adverse effects*
  • Chlorpheniramine / therapeutic use
  • Glucocorticoids / adverse effects*
  • Glucocorticoids / therapeutic use
  • Growth Disorders / chemically induced*
  • Growth Disorders / diagnosis
  • Humans
  • Hydrocortisone / blood
  • Iatrogenic Disease
  • Male
  • Rhinitis, Allergic, Perennial / drug therapy

Substances

  • 17-Hydroxycorticosteroids
  • Anti-Allergic Agents
  • Glucocorticoids
  • Chlorpheniramine
  • Betamethasone
  • Hydrocortisone